

Anti-DLL4 Reference Antibody (navicixizumab)

Recombinant Antibody Catalog # APR10040

Product Information

Application FC, Kinetics, Animal Model

Primary Accession

Reactivity

Clonality

Isotype

Calculated MW

Q9NR61

Human

Monoclonal

IgG2SA

74605

Additional Information

Target/Specificity DLL4

Endotoxin

Conjugation Unconjugated

Expression system CHO Cell

Format Purified monoclonal antibody supplied in PBS, pH6.0, without

preservative. This antibody is purified through a protein A column.

Protein Information

Name DLL4

Function Involved in the Notch signaling pathway as Notch ligand

(PubMed: 11134954). Activates NOTCH1 and NOTCH4. Involved in


angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting (PubMed: 20616313). Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate (PubMed: 17728344).

Cellular Location Cell membrane; Single-pass type I membrane protein


Tissue Location Expressed in vascular endothelium.

Images


Anti-DLL4 Reference Antibody (navicixizumab) on SDS-PAGE under reducing (R) condition. The gel was



stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-DLL4 Reference Antibody (navicixizumab)is more than 95% ,determined by SEC-HPLC.



Immobilized human VEGF165 His at 2 µg/mL can bind Anti-DLL4 Reference Antibody (navicixizumab),EC50=0.01191 µg/mL

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.